Drug Profile
Anfibatide - Lee's Pharmaceutical
Alternative Names: Antiplatelet thrombolysin for injection - Lee's Pharmaceutical; Declotana; ZK 001Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Lee's Pharmaceutical
- Class Antiplatelets; Ischaemic heart disorder therapies; Peptides; Snake venoms
- Mechanism of Action Adhesion receptor antagonists; Platelet glycoprotein GPIb-IX complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-II for Myocardial infarction in China (IV)
- 26 May 2020 Lee's Pharmaceutical suspends prior to enrolment, a phase I trial in Healthy volunteers in China (IV) (for protocol optimisation) (NCT04404790)
- 18 Jul 2019 Lee's Pharmaceuticals plans a phase II trial in Thrombotic thrombocytopenic purpura in China in July 2019 (NCT04021173)